{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:50Z","timestamp":1790916830772,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":188,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005687","name":"Goethe-Universit\u00e4t Frankfurt am Main","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","award":["CA209-499"],"award-info":[{"award-number":["CA209-499"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101319","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T05:54:30Z","timestamp":1784354070000},"page":"101319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Fumarate hydratase-deficient renal cell carcinoma \u2013 results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4313-0895","authenticated-orcid":false,"given":"Marit","family":"Ahrens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine Gross","family":"Goupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterini","family":"Boleti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc Oliver","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bedke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Begona","family":"Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Ivanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Rottey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Fl\u00f6rcken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose P.","family":"Maroto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoukje","family":"Oosting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindrich","family":"Kopecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Zsch\u00e4bitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Boegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Buchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenter","family":"Niegisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goebell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Waddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Priou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margitta","family":"Retz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Siemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Deckbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Burkholder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"St\u00f6hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2026.101319_bib0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumors of the urinary system and male genital organs \u2013 part A: renal, penile, and testicular tumors","volume":"70","author":"Moch","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ctarc.2026.101319_bib0002","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/PAS.0000000000000617","article-title":"Fumarate hydratase- deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syn- drome","volume":"40","author":"Trpkov","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ctarc.2026.101319_bib0003","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer","volume":"30","author":"Tomlinson","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ctarc.2026.101319_bib0004","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pathol.2024.08.013","article-title":"Fumarate hydratase-deficient renal cell carcinoma: a single institution-based study of 29 patients by clinicopathological, immunohistochemical and genetic approaches","volume":"57","author":"Lee","year":"2025","journal-title":"Pathology"},{"key":"10.1016\/j.ctarc.2026.101319_bib0005","doi-asserted-by":"crossref","unstructured":"Alam N., Rowan A., Wortham N., Pollard P., Mitchell M, Tyrer J., Barclay E., Calonje E, Manek S, Adams S. et al (2003) Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyo- matosis and renal cancer.","DOI":"10.1093\/hmg\/ddg148"},{"key":"10.1016\/j.ctarc.2026.101319_bib0006","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1158\/1078-0432.CCR-20-4367","article-title":"Comprehensive molecular characterization and response to therapy in fumarate hydratase-deficient renal cell carcinoma","volume":"27","author":"Gleeson","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101319_bib0007","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/PAS.0000000000000163","article-title":"Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry","volume":"38","author":"Chen","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ctarc.2026.101319_bib0008","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/jclinpath-2019-205924","article-title":"Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases","volume":"72","author":"Pan","year":"2019","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.ctarc.2026.101319_bib0009","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/gcc.22905","article-title":"Hereditary leiomyomato- sis and renal cell carcinoma syndrome associated uterine smooth muscle tumors: bridging morpho- logy and clinical screening","volume":"60","author":"Garg","year":"2021","journal-title":"Genes Chromos. Cancer"},{"key":"10.1016\/j.ctarc.2026.101319_bib0010","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/PAS.0000000000001372","article-title":"A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients","volume":"44","author":"Lau","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101319_bib0011","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101319_bib0012","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.ctarc.2026.101319_bib0013","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101319_bib0014","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"CheckMate 9ER Investigators. Nivolumab plus Cabozantinib versus Sunitinib for advanced Renal-Cell Carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101319_bib0015","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101319_bib0016","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2021.04.009","article-title":"Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma","volume":"151","author":"Carril-Ajuria","year":"2021","journal-title":"EJC"},{"issue":"15suppl","key":"10.1016\/j.ctarc.2026.101319_bib0017","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1200\/JCO.2020.38.15_suppl.5004","article-title":"Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer","volume":"38","author":"Srinivasan","year":"2020","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101319_bib0018","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4143\/crt.2019.086","article-title":"Bevacizumab plus erlotinib combination therapy for advanced hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma: a multicenter retrospective analysis in Korean patients","volume":"51","author":"Choi","year":"2019","journal-title":"Canc. Res. Treat"},{"issue":"5_suppl","key":"10.1016\/j.ctarc.2026.101319_bib0019","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/JCO.2025.43.5_suppl.443","article-title":"Lenvatinib plus tislelizumab as first-line therapy in advanced fumarate hydratase-deficient renal cell carcinoma: a single-center, single-arm, phase II study","volume":"43","author":"Kong","year":"2025","journal-title":"JCO"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101319_bib0020","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/jamaoncol.2025.2497","article-title":"Sintilimab pluas axitinib for advanced fumarate hydratase-deficient renal cell carcinoma \u2013 a phase 2 nonrandomized clinical trial","volume":"11","author":"Zhang","year":"2025","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101319_bib0021","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eururo.2022.05.029","article-title":"Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma","volume":"83","author":"Xu","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ctarc.2026.101319_bib0022","series-title":"NCCN Clinical Practice Guidelines in Oncology: Renal cell carcinoma, Version 1","year":"2026"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101319_bib0023","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101319_bib0024","series-title":"Konsultationsfassung S3-Leitlinie Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms","author":"Langer","year":"2024"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101319_bib0025","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 world health organization classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur. Urol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101319_bib0026","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.annonc.2025.03.016","article-title":"Prospective randomized phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial","volume":"36","author":"Bergmann","year":"2025","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101319_bib0027","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1016\/j.clgc.2020.02.009","article-title":"Multicentric analytical and inter-observer comparability of four clinically developed programmed death-ligand 1 immunohistochemistry assays in advanced clear-cell Renal Cell Carcinoma","volume":"18","author":"Sommer","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101319_bib0028","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus versus Sunitinib prospective evaluation in metastatic non-clear-cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial","volume":"69","author":"Tannir","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ctarc.2026.101319_bib0029","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s44178-024-00071-2","article-title":"Consensus on clinical diagnosis and treatment of fumarate hydratase-deficient renal cell carcinoma","volume":"3","author":"Shen","year":"2024","journal-title":"Holist. Integr. Oncol."},{"key":"10.1016\/j.ctarc.2026.101319_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.906014","article-title":"Targeting strategies in the treatment of fumarate deficient renal cell carcinoma","volume":"12","author":"Lindner","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2026.101319_bib0031","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cmet.2023.04.017","article-title":"Cancer-cell-derived fumarate suppresses the anti- tumor capacity of CD8+ T cells in the tumor microenvironment","volume":"35","author":"Cheng","year":"2023","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101319_bib0032","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41419-025-07752-4","article-title":"Oncometabolite fumarate facilitates PD-L1 expression and immune evasion in clear cell renal cell carcinoma","volume":"16","author":"Gao","year":"2025","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.ctarc.2026.101319_bib0033","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1038\/s41467-025-59513-8","article-title":"Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2026.101319_bib0034","article-title":"PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: results from a GETUG multicenter retrospective cohort","volume":"205","author":"Naffrichoux","year":"2024","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101319_bib0035","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.3390\/ijms25073916","article-title":"Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Non-Clear Cell Renal Cell Carcinoma","volume":"25","author":"Chraba\u0144ska","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101319_bib0036","doi-asserted-by":"crossref","first-page":"S1301","DOI":"10.1016\/j.annonc.2025.08.3211","article-title":"2595MO Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing ipilimumab\/nivolumab vs standard of care as first-line treatment. Abstract only","volume":"36","author":"Ahrens","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101319_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116816","article-title":"Papillary renal cell carinoma \u2013 exploratory results of the SUNNIFORECAST trial comparing ipilimumab plus nivolumab vs standard of care as first-line therapy based on cenral pathological review","volume":"243","author":"Ahrens","year":"2026","journal-title":"Eur. J. Canc."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:00:06Z","timestamp":1790913606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":37,"alternative-id":["S2468294226002303"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101319","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fumarate hydratase-deficient renal cell carcinoma \u2013 results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101319"}}